Legend Biotech Shares Plunge 8% on $225M ADS Offering Filing
Summary
Legend Biotech shares fell 8% after the company filed for a $225 million American Depositary Share (ADS) offering. This follows yesterday's announcement and preliminary prospectus filing for the same offering. The capital raise represents approximately 3.6% dilution relative to the company's market cap, and the sharp share price decline reflects investor concerns over the offering's impact.
At the time of this announcement, LEGN was trading at $31.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $16.24 to $45.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.